Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China
· Delayed Price · Currency is CNY 29.14
+0.73 (2.57%)
Mar 10, 2026, 4:00 PM EDT
SHE:301089 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -47.39 | -19.88 | 243.07 | 286.54 | 65.71 | 112.8 | Upgrade
|
| Depreciation & Amortization | 47.66 | 47.66 | 46.59 | 40.52 | 30.92 | 17.39 | Upgrade
|
| Other Amortization | 0.88 | 0.88 | 0.52 | 0.47 | 0.57 | 0.6 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | - | -0.03 | - | 0.23 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.42 | 1.42 | 4.22 | 1.03 | 1.34 | 0.98 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.55 | -1.55 | -7.12 | -5.77 | -0.63 | -0.66 | Upgrade
|
| Provision & Write-off of Bad Debts | 4.08 | 4.08 | 4.48 | -5.11 | 2.28 | 0.13 | Upgrade
|
| Other Operating Activities | -94.49 | 9.92 | 11.11 | 12.48 | 9.5 | 13.92 | Upgrade
|
| Change in Accounts Receivable | 72.83 | 72.83 | -57.67 | -100.76 | -27.49 | -22.27 | Upgrade
|
| Change in Inventory | 14.55 | 14.55 | 37.75 | -72.92 | -21.38 | -47.43 | Upgrade
|
| Change in Accounts Payable | -19.28 | -19.28 | -264.08 | 172.6 | -61.71 | -10.29 | Upgrade
|
| Change in Unearned Revenue | - | - | - | - | 16.83 | 15.82 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | - | 40.99 | 38.49 | Upgrade
|
| Operating Cash Flow | -29.25 | 102.67 | 26.95 | 268.85 | 58.19 | 120 | Upgrade
|
| Operating Cash Flow Growth | - | 280.91% | -89.98% | 361.99% | -51.51% | 38.93% | Upgrade
|
| Capital Expenditures | -61.25 | -83.91 | -185.22 | -148.33 | -112.73 | -74.12 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.42 | 0.6 | 0.04 | 0.08 | 10 | 0.08 | Upgrade
|
| Investment in Securities | -45 | -60 | 56.57 | -20.4 | -220 | - | Upgrade
|
| Other Investing Activities | 4.38 | 3.43 | - | 6.24 | - | 0.65 | Upgrade
|
| Investing Cash Flow | -101.45 | -139.88 | -128.61 | -162.41 | -322.73 | -73.39 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 90 | 131.4 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 244.76 | Upgrade
|
| Total Debt Issued | - | - | - | 90 | 131.4 | 244.76 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -193.82 | - | Upgrade
|
| Long-Term Debt Repaid | - | -0.94 | -40 | -115.42 | -44.93 | -228.31 | Upgrade
|
| Total Debt Repaid | -0.94 | -0.94 | -40 | -115.42 | -238.75 | -228.31 | Upgrade
|
| Net Debt Issued (Repaid) | -0.94 | -0.94 | -40 | -25.42 | -107.35 | 16.45 | Upgrade
|
| Issuance of Common Stock | - | - | 21.6 | - | 558.81 | - | Upgrade
|
| Common Dividends Paid | - | -31.64 | -50.67 | -14.98 | -7.92 | -9.6 | Upgrade
|
| Dividends Paid | - | -31.64 | -50.67 | -14.98 | -7.92 | -9.6 | Upgrade
|
| Other Financing Activities | -1.32 | - | - | - | -11.3 | -0.59 | Upgrade
|
| Financing Cash Flow | -2.25 | -32.57 | -69.07 | -40.4 | 432.23 | 6.26 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.61 | 0.83 | 0.11 | 0.97 | -0.73 | -0.42 | Upgrade
|
| Net Cash Flow | -132.34 | -68.95 | -170.62 | 67.01 | 166.97 | 52.45 | Upgrade
|
| Free Cash Flow | -90.5 | 18.76 | -158.27 | 120.52 | -54.53 | 45.88 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | 350.96% | Upgrade
|
| Free Cash Flow Margin | -24.63% | 4.45% | -18.94% | 15.36% | -10.85% | 8.69% | Upgrade
|
| Free Cash Flow Per Share | -0.76 | 0.15 | -1.26 | 0.95 | -0.55 | 0.48 | Upgrade
|
| Cash Income Tax Paid | 15.11 | -7.98 | 237 | 56.09 | 20.74 | 29.6 | Upgrade
|
| Levered Free Cash Flow | -76.69 | 34.73 | -156.56 | 106.83 | -139.19 | 58.7 | Upgrade
|
| Unlevered Free Cash Flow | -76.58 | 34.76 | -156.35 | 108.94 | -133.48 | 67.37 | Upgrade
|
| Change in Working Capital | 60.14 | 60.14 | -275.92 | -61.28 | -51.49 | -25.39 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.